Citigroup Inc Arbutus Biopharma Corp Transaction History
Citigroup Inc
- $196 Billion
- Q2 2025
A detailed history of Citigroup Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Citigroup Inc holds 229,814 shares of ABUS stock, worth $781,367. This represents 0.0% of its overall portfolio holdings.
Number of Shares
229,814
Previous 261,836
12.23%
Holding current value
$781,367
Previous $913,000
22.23%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ABUS
# of Institutions
188Shares Held
112MCall Options Held
864KPut Options Held
708K-
Morgan Stanley New York, NY23.8MShares$80.9 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$45.2 Million27.3% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.3 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.47MShares$32.2 Million1.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$30.9 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $510M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...